COMPOSITIONS OF MARINE BOTANICALS TO PROVIDE NUTRITION TO AGING AND ENVIRONMENTALLY DAMAGED SKIN

Abstract

A method of treating skin is disclosed. The method can include topically applying to skin an effective amount of a composition that includes water, a Crithmum maritimum extract, and an Ulva lactuca extract.

Claims

1. A method of treating skin, the method comprising topically applying to skin an effective amount of a composition comprising: (a) water; (b) a Crithmum maritimum extract; and (c) an Ulva lactuca extract, wherein the composition moisturizes the skin, increases skin firmness, or reduces the appearance of a fine line or a wrinkle on the skin.

2. The method of claim 1, wherein the composition moisturizes skin.

3. The method of claim 2, wherein the composition is applied to dry skin.

4. The method of claim 1, wherein the composition is applied to the fine line or the wrinkle and reduces the appearance of the fine line or the wrinkle.

5. The method of claim 1, wherein the composition increases skin firmness.

6. The method of claim 1, wherein the composition is formulated as a cream or lotion.

7. The method of claim 1, wherein the composition is formulated as a gel.

8. The method of claim 1, wherein the composition is formulated as a solution.

9. The method of claim 1, wherein the topical skin composition is formulated as an oil-in-water emulsion.

10. The method of claim 1, wherein the composition is free of parabens.

11. The method of claim 1, wherein the composition includes 0.001% to 5% by weight of the Crithmum maritimum extract and 0.001% to 5% by weight of the Ulva lactuca extract.

12. The method of claim 1, wherein the composition does not include an algae extract from Monostroma.

13. The method of claim 1, wherein the Crithmum maritimum extract includes falcarinol or falcarindiol, and wherein the Ulva lactuca extract includes a hydrolysate of Ulva lactuca proteins.

14. The method of claim 1, wherein the composition further includes: (d) glycerin; (e) citric acid; and potassium sorbate.

15. The method of claim 1, wherein the composition further includes: (d) Helianthus annuus seed oil; (e) caprylic/capric triglyceride; and tocopherol or tocopherol acetate.

16. The method of claim 1, wherein the composition further includes: (d) glycerin; (e) citric acid; tocopherol or tocopherol acetate; and (g) hydrogenated palm glyceride.

17. The method of claim 1, wherein the composition further includes (d) glycerin; and (e) citric acid.

18. The method of claim 17, wherein the composition further includes: (f) caprylic/capric triglyceride; (g) tocopherol or tocopherol acetate; (h) hydrogenated palm glyceride; (i) glyceryl stearate; (j) cetyl palmitate; and (k) cocoglycerides.

19. The method of claim 1, wherein the composition further comprises an additional algae extract.

Description

EXAMPLES

[0067] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1

Chronic Anti Aging Study

[0068] Materials and Methods: The following study was conducted to determine if a marine composition comprising 5.0% CODIAVELANE, 1.0% AOSAINE, 2.0% Monostroma, 5.0% OLEAPHYCOL-CM, and 3.0% CHLORELLINE (a non-limiting example of a botanical blend of the present invention) provides long-term visual and measurable anti-aging benefits on the human face. Vehicle A (Table 1) was used as a control. Twenty panelists applied the composition twice a day, morning and evening on their face.

TABLE-US-00001 TABLE 1 Vehicle A* Phase Ingredient % In Formula A Water 58.4 A Glycereth-26 5.0 A Hispagel 5.0 A Disodium EDTA 0.05 A Carbopol 940, 2% 15.0 B Lecinol S-10 1.0 C Cosmowax J 1.25 C Finsolve TN 6.0 C Dimethicone 0.5 C Isostearyl Alcohol 1.25 C Cetyl Alcohol 0.7 C Silica 0.35 D Triethanolamine, 99% 1.16 D Water 1.60 E Germaben II 1.0 F Sodium PCA 0.11 F Prodew 400 0.7 F Tocopheryl Acetate 0.1 F Phospholipid EFA 0.82 *Procedure to make Vehicle A: Add the ingredients in A to vessel, in order, at room temperature, mixing between additions. Begin heating to 75 C. At 50 C., add B. At 75 C. add C, in order, mixing between additions. As mixture cools, add D at 65 C. At 45 C., add E and F.

[0069] The panelists were monitored for skin condition at the beginning of the study (i.e. before treatment); at four weeks after the treatment; and at eight weeks after the treatment. They were evaluated for face and neck moisture, dryness, surface fine lines, canthus wrinkles, firmness, softness, and clarity. The results identified in Table 2 were obtained by using the following procedures. Face and neck moisture were evaluated using impedance measurements, an electrical conductivity measurement using the Nova Dermal Phase Meter. Dryness, surface fine lines, and softness were determined by an expert grader using a calibrated visual analog scale from 1 to 10. Skin softness was measured by Gas Bearing Electrodynamometer. Surface fine lines were counted and the severity of the lines evaluated according to the Packman-Gans method, (1978), using weighted scoring. Dryness was evaluated using a calibrated visual analog scale from 1 to 10. Firmness was evaluated using a Hargens ballistometer, a device that evaluates the elasticity and firmness of the skin by dropping a small body onto the skin and recording its first two rebound peaks. As firmness decreases, the second peak will be smaller in comparison to the first. Clarity was evaluated using a Minolta Chromameter, which measures the total light reflected from the skin compared to the amount of red and brown/yellow light. These measurements were mathematically analyzed to determine the clarity of the skin. Canthus wrinkles were evaluated four and eight weeks after treatment by comparing the silicone replicas (negative impressions) made of the individuals' skin at baseline. The replicas were evaluated by computer image analysis to determine the number and depth of the wrinkles.

[0070] Results: As shown in Tables 2 and 3, continued improvement was seen for the skin condition parameters throughout the 8 weeks of the study. The composition comprising the marine botanicals performed better than the vehicle A control. A continued improvement was also seen with vehicle A. This was due to the moisturizing ingredients in the vehicle A formula.

TABLE-US-00002 TABLE 2 Effects of marine botanical composition on the human skin % Improvement Compared to Baseline Vehicle A Vehicle A + Botanical Blend Skin Benefit Week 4 Week 8 Week 4 Week 8 Cheek Moisture 20.6 33.5 33.6 48.0 Neck Moisture 27.9 36.5 35.3 49.9 Firmness 12.1 24.4 17.0 29.0 Softness/Suppleness 22.2 32.4 26.0 41.1 Canthus Wrinkles 17.2 28.4 24.0 43.3 Clarity 4.8 8.5 5.8 11.3 Surface Fine Lines 18.1 29.2 23.1 41.2 Dryness 32.7 51.0 36.4 58.6

TABLE-US-00003 TABLE 3 Panelist self assessment of the marine botanical composition during an 8-Week Treatment Period % of Panelists Perceiving Much Skin Greater Improved Skin Condition* Benefit Marine botanicals Skin Vehicle A in Vehicle A Condition 2 Weeks 4 Weeks 8 Weeks 2 Weeks 4 Weeks 8 Weeks Dryness 53.3 66.7 86.7 60.00 80.00 100.0 Smoothness 46.7 60.0 80.0 60.0 73.3 100.0 Lines and 6.7 26.7 60.0 20.00 46.7 66.7 Wrinkles Firmness 6.7 46.7 66.7 20.00 60.0 80.0 Softness 33.3 46.7 73.3 53.3 60.0 86.7 Healthy 13.3 26.7 46.7 26.7 33.3 66.7 Glow Elasticity 26.7 53.3 66.7 20.00 66.7 86.7 Looks 13.3 46.7 73.3 20.0 60.0 86.7 Younger Looks 20.0 46.7 80.00 26.7 60.00 86.7 Healthier *Fifteen panelists in each of the treatment cells participated in the study. After 2, 4, and 8 weeks of product use, the panelists rated their skin condition on a 5-point scale which compared the condition at the start of the study. The scale ranged from the assessed parameter being much less improved, somewhat less improved, no change, somewhat greater improved, and much greater improved. The values represent the percent of panelists who perceived much greater improvement at the given point in time. A person of ordinary skill in the cosmetic arts understands the meaning of the terms used in the far left column of Table 3.

EXAMPLE 2

Stratum Corneum Turnover Study

[0071] Materials and Methods: The following procedure was utilized to estimate stratum corneum turnover rates on human skin, which results directly from epidermal activation. Four sites were marked on the forearm using a plastic template. Baseline readings of color intensity were determined using a Minolta Chromameter (b* value listed in Table 4). Occlusive Hilltop chambers (2 cm diameter) containing 0.05 ml Mary Kay SUN ESSENTIALS Sunless Tanning Lotion product with dihydroxyacetone (DHA) were placed on the sites. After 6 hours, these patches were removed, and 18 hours later, the color intensity was again determined using the Chromameter. The b* values in Table 4 were calculated as the difference between the reading and the baseline. Panelists applied the formula in Table 5 to the brown spots in the morning and evening during the ensuing 10 days. Chromameter readings were repeated after 4, 7, and, 10 days. The color decay slope was calculated as the percent loss per day, and the transit time determined by extrapolating to 100% loss of color.

[0072] Results: The results of this study (Table 4) indicate that the combination of Sea Fennel, Monostroma, and CHLORELLINE increased the rate at which the stratum corneum replaced itself when compared to the vehicle B (Table 5) that was used to incorporate these three ingredients. The effects were concentration-dependent. The increases in stratum corneum replacement rate show that Sea Fennel, Monostroma, and CHLORELLINEO in the composition activate and/or stimulate the epidermis of the skin.

TABLE-US-00004 TABLE 4 Effects of Sea Fennel, Monostroma and CHLORELLINE on Human Stratum Corneum Turnover Rate % Change in Stratum Stratum Corneum Corneum Renewal Renewal Rate Rate vs. No Composition Tested ( b*/Day) Treatment Control Untreated 0.590 Vehicle B (Table 5) 0.632 7 Vehicle B + 0.660 12 0.5% Monostroma + 1.0% CHLORELLINE Vehicle B + 0.691 17 2.0% Monostroma + 3.0% CHLORELLINE

TABLE-US-00005 TABLE 5 Vehicle B* Phase Ingredient % In Formula A Water 87.86 A Disodium EDTA 0.10 A Ferulic Acid 0.01 A Carbopol ETD 2020 0.30 B Butylene Glycol 5.00 B Methylparaben 0.20 C L-Arginine 0.50 C Water 5.00 D Triethanolamine, 99% 0.25 E DMDM Hydantoin 0.20 F Vegetech Night Breeze 0.01 F Sea Rocket Extract 0.01 F Elias Blend 0.05 F Sea Fennel Extract 0.01 G Unispheres PACE 0.50 *Procedure to make Vehicle B: Add the ingredients in B to vessel, in order, at room temperature, mixing between additions. Add phase A to B at room temperature. Add C, D, E and F in order, mixing between additions at room temperature. Slowly add G at the end at room temperature.

[0073] All of the compositions and/or methods and/or apparatus disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and/or apparatus and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

[0074] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. [0075] U.S. Pat. No. 4,758,283 [0076] U.S. Pat. No. 5,720,963 [0077] U.S. Pat. No. 6,495,126 [0078] Barany and Merrifield, In: The Peptides, Gross and Meienhofer (Eds.), Academic Press, NY, 1-284, 1979. [0079] Blumenthal et al., In: Herbal Medicine, Expanded Commission E Monographs, 1.sup.st Ed., Integrated Medicine Communications, Newton , Mass., 2000. [0080] Fang et al., Univ. of Cairo, Bull. Fac. Agric, 43(1):31-44, 1992. [0081] Houghten, Proc. Natl. Acad. Sci. USA, 82(15):5131-5135, 1985. [0082] Merrifield, Science, 232(4748):341-347, 1986. [0083] Packman-Gans method, J. Soc. Cosmetic Chem. 29:70 (1978 [0084] Packman-Gans, J. Soc. Cosmetic Chem., 29:70, 1978. [0085] Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990. [0086] Ruperez et al., J. Agric. Food Chem., 50(4):840-845, 2002. [0087] Schiltz et al. J. Investigative Dermatology, 87:663-667, 1986. [0088] Stewart and Young, In: Solid Phase Peptide Synthesis, 24-66, Freeman, San Francisco, 1969. [0089] Tam et al., J. Am. Chem. Soc., 105:6442, 1983. [0090] Winsauer-Burkett, Fennel, Alt MedDex, June 2001.